Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
RANDOMIZED CONTROLLED TRIAL
Salim Yusuf, Jackie Bosch, Gilles Dagenais, Jun Zhu, Denis Xavier, Lisheng Liu, Prem Pais, Patricio López-Jaramillo, Lawrence A Leiter, Antonio Dans, Alvaro Avezum, Leopoldo S Piegas, Alexander Parkhomenko, Katalin Keltai, Matyas Keltai, Karen Sliwa, Ron J G Peters, Claes Held, Irina Chazova, Khalid Yusoff, Basil S Lewis, Petr Jansky, Kamlesh Khunti, William D Toff, Christopher M Reid, John Varigos, Gregorio Sanchez-Vallejo, Robert McKelvie, Janice Pogue, Hyejung Jung, Peggy Gao, Rafael Diaz, Eva Lonn
BACKGROUND: Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without cardiovascular disease. METHODS: In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants in 21 countries who did not have cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo...
May 26, 2016: New England Journal of Medicine
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
